Issue link: https://www.e-digitaleditions.com/i/1509086
34 Pharmaceutical Technology ® Trends in Formulation 2023 eBook PharmTech.com IPOPBA - stock.adobe.com A head of CPHI Barcelona, which will occur October 24–26, 2023, the CPHI Annual Re- port explores future trends, challenges, and opportunities (1). Featuring a panel of more than 12 industry analysts and insights from 400 phar- maceutical executives, the report provides a window into both near-term and medium-term opportunities in the pharma sector. In this article, the author delves into the implications of artificial intelligence (AI) on drug development and pharmaceutical manufacturing. Advances in AI are affecting many aspects of society and business today, and pharmaceutical and biotech sectors are no exception. A study estimated that global gross domestic product (GDP) could be up to 14% higher in 2030 as a result of AI—the equivalent of an addi- tional US$15.7 trillion—making it the biggest commer- cial opportunity in today's economy (2). AI includes multiple applications comprising deep learning, generative adversarial networks (GANs), reinforcement learning (RL), transfer learning, and natural language processing (NLP), underscoring the maturity of the field as the tools and approaches are tailored for discrete processing frameworks. One recent entry to the AI solution set that has captured the interest of society, industry, and investors alike is generative AI. Generative AI is based on the gen- erative pre-trained transformer (GPT) architecture, a model that uses unsupervised learning to generate human-like text based on the context and input it re- ceives. This development is significant as it is the first architecture that can accept unstructured input. The ability to handle unstructured data inputs is revolu- tionary in the field of NLP. This means textual data, images, audio, and other forms of data that do not con- form to a predefined data model or schema can be used for analysis, requiring no special preprocessing or ex- pertise to use the system. Because much of the data on the Internet is unstructured, this means industry can The Impact of AI on Pharma Bikash Chatterjee is president and chief science officer at Pharmatech Associates–a USP Company. CPHI's Annual Report predicts huge impact of AI on drug development and manufacturing.